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Abstract
Background: Calcium-permeable channels are known to have roles in many mammalian cell types but the expression 
and contribution of such ion channels in synovial cells is mostly unknown. The objective of this study was to 
investigate the potential relevance of Transient Receptor Potential Melastatin 3 (TRPM3) channel to fibroblast-like 
synoviocytes (FLSs) of patients with rheumatoid arthritis.
Methods: The study used RT-PCR and immunofluorescence to detect mRNA and protein. Intracellular calcium 
measurement detected channel activity in a FLS cell-line and primary cultures of FLSs from patients with rheumatoid 
arthritis. Enzyme-linked immunosorbent assays measured hyaluronan.
Results: Endogenous expression of TRPM3 was detected. Previously reported stimulators of TRPM3 sphingosine and 
pregnenolone sulphate evoked sustained elevation of intracellular calcium in FLSs. The FLS cell-line showed an initial 
transient response to sphingosine which may be explained by TRPV4 channels but was not observed in FLSs from 
patients. Blocking antibody targeted to TRPM3 inhibited sustained sphingosine and pregnenolone sulphate responses. 
Secretion of hyaluronan, which contributes adversely in rheumatoid arthritis, was suppressed by pregnenolone 
sulphate in FLSs from patients and the effect was blocked by anti-TRPM3 antibody.
Conclusions: The data suggest that FLSs of patients with rheumatoid arthritis express TRPM3-containing ion channels 
that couple negatively to hyaluronan secretion and can be stimulated by pharmacological concentrations of 
pregnenolone sulphate.
Background
Transient Receptor Potential (TRP) was discovered in
Drosophila melanogaster as a component of the visual
response to bright light. Subsequently, 28 related genes
were discovered in mammals, found to be widely
expressed and shown to be involved in various chemical
and temperature sensing mechanisms [1,2]. The mamma-
lian TRP channels are divided into subgroups according
to amino acid sequence similarities; one subgroup is the
M (melastatin) subgroup of which there are eight mem-
bers, while other subgroups include the V (vanilloid) and
C (canonical) subgroups. We previously reported on
expression and function of TRPC channels in fibroblast-
like synoviocytes (FLSs) [3]. There have also been indica-
tions of TRPV1, TRPV4 and TRPM8 functions in FLSs
[4,5], but regulation and importance of TRP channels in
the synovial lining is relatively unknown. Here we focus
on TRPM3 [6-11]. When over-expressed in cell-lines
TRPM3 forms Ca2+-permeable non-selective cationic
channels at the plasma membrane that can be stimulated
by factors including sphingosine and pregnenolone
[8,10]. Activity of endogenous TRPM3 channels and the
biological functions of such channels are poorly under-
stood but a recent seminal study showed expression in
pancreatic β-cells and suggested coupling of preg-
nenolone to insulin secretion via TRPM3 [10]. Preg-
nenolone is derived from cholesterol and the precursor
for steroid hormones including the corticosteroids,
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androgens, oestrogen and progesterone. It is sulphated in
vivo and the sulphated form (pregnenolone sulphate) is
suggested to have biological actions, including through
glutamate and γ-aminobutyric acid receptors of neurones
[12,13].
Rheumatoid arthritis (RA) is a common and debilitat-
ing disease affecting large numbers of people world-wide.
Inflammation of the synovial lining is a striking feature of
the disease and is contributed to strongly by hyperplasia
of FLSs [14-16]. Hyaluronan is secreted by FLSs and is a
well-recognised lubricant of physiological joints, but
excess hyaluronan from FLSs and degradation products
of hyaluronan contribute to RA [17]. Furthermore,
hyaluronan from other cell types may have general
adverse consequences in inflammatory conditions,
including in atherosclerosis [18,19].
In this study we investigated TRPM3 and its stimula-
tors by using a model FLS cell-line and primary cultures
of FLSs from patients diagnosed with RA.
Methods
HIG-82 cells
HIG-82 cells are a fibroblast-like synoviocyte (FLS) cell-
line from soft tissue lining the knee joints of rabbits
[20,3]. Cells were cultured in Ham's F-12 medium (Gibco,
UK) containing 10% fetal calf serum, 100 units·ml-1 peni-
cillin and 100 μg·ml-1  streptomycin. Cells were main-
tained in a humidified atmosphere of 5% CO2 in air and
re-plated on 96-well plates 24 hr prior to experiments.
The cells stained positively for CD55 and negatively for
CD68, supporting their identification as FLS-like cells [3].
Synovial tissue
Tissue biopsies were obtained during arthroscopy from
the synovial lining of knee joints of patients diagnosed
with RA at the Academic Unit of Musculoskeletal Dis-
ease, Chapel Allerton Hospital, Leeds. Ethical approval
was given by the Local Ethics Committee. Patient
informed consent was obtained. No attempt was made to
correlate findings with the severity of the RA or other
patient characteristics. Patient therapy was standard dis-
ease-modifying anti-rheumatic drugs but not anti-tumor
necrosis factor (TNF) therapies or high-dose steroids.
Primary cultures of FLSs
Synovial biopsies were washed with phosphate-buffered
saline and digested with 0.25% type 1A collagenase (Stem
Cell Technologies, UK) for 4 hr at 37°C and FLSs were
then cultured in DMEM/F-12 + Glutamax (Gibco, UK)
containing 10% fetal calf serum, 100 units·ml-1 penicillin
and 100 μg·ml-1 streptomycin. FLSs were maintained in a
humidified atmosphere of 5% CO2 in air and replated on
multi-well plates prior to experiments.
Over-expression of TRPV4
Chinese hamster ovary (CHO) K1 cells stably expressing
human TRPV4 were maintained in Ham's F12 (Gibco,
UK) in the presence of 1 mg ml-1 G418 (Sigma, UK).
RT-PCR
Total RNA was extracted using a Tri-reagent protocol fol-
lowed by DNase I (Ambion) treatment. 1 μg of total RNA
was used for reverse transcription (RT) based on oligo-
dT primers and AMV RT enzyme. TRPM3 PCR primers
were (5'-3') AGCAGTTCTACCTAACGT (forward
primer) and CTTGCTCGACTAGACTTG (reverse
primer). The expected product size was 268 bp. The
specificity of the RT-PCR was verified by reactions with-
out RT (-RT) and by sequencing of the PCR product
(University of Leeds, UK).
Labeling with antibody
Tissue sections (4 μm thick) were cut from snap-frozen
biopsy samples, fixed with acetone and stored at -80°C
until use (immunofluorescence labeling) or fixed with 1%
paraformaldehyde (immunohistochemistry). Staining
was according to standard protocols: Briefly, sections
were incubated with primary antibody over night at 4°C
and secondary antibody (goat anti-rabbit IgG-FITC or
HRP) for 1 hr at room temperature. Slides were mounted
(Vector Labs, UK) and imaged with a confocal or bright-
field microscope. Anti TRPM3 (TM3E3) and anti-CD55
(clone 67, Serotec) primary antibodies were used at 1:500
and 1:200 dilutions respectively. TM3E3 was described
previously [11].
Hyaluronan secretion
Primary FLSs were cultured in 6 well plates for 24 hr
without serum starvation and then fresh medium was
added containing PregS, dexamethasone, TNF or vehicle.
Incubations with antibodies occurred in culture medium
for 2 hr prior to addition of compounds. Supernatants
were collected after 24 hr, frozen and analysed using an
enzyme-linked immunosorbent assay (ELISA) that
detects hyaluronan (HA ELISA kit, Corgenix).
Intracellular Ca2+ measurement
Ca2+ was measured using a FlexStation II controlled by
SoftMax Pro 4.7.1 software (Molecular Devices, USA).
Cells were plated at 60-70% confluence on 96-well
square-bottomed clear plates (Nunclon, UK) 24 hr before
experiments. Immediately prior to recording, cells were
incubated for 1 hr at 37°C in SBS (see below) containing
10 μM fura-2 acetoxymethyl ester and then washed with
SBS 2-3 times before adding fresh SBS. Incubations with
TM3E3 antibody occurred for 2 hr prior to the incuba-
tion with the fluorescent dye, during the incubation and
the washing period (i.e. for 3.5 hr prior to recording data).
Excess TM3E3 was removed immediately prior to experi-Ciurtin et al. BMC Musculoskeletal Disorders 2010, 11:111
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ments. Excitation light alternated between 340 and 380
nm, while emission was filtered at 510 nm. Experiments
were at room temperature (21 ± 3°C). Standard bath solu-
tion (SBS) contained (mM): 130 NaCl, 5 KCl, 1.2 MgCl2,
1.5 CaCl2, 8 glucose and 10 Hepes (titrated to pH 7.4
using NaOH and adjusted to 290 mOsm using mannitol).
Ca2+-free SBS was SBS in which CaCl2 was replaced by
0.4 mM EGTA.
Reagents
All reagents were from Sigma (UK) or BDH (British Drug
House, Poole, UK). Sphingosine was prepared as a 20 mM
stock in 100% ethanol and stored at -20°C, pregnenolone
sulphate as a 100 mM stock in DMSO and stored at 4°C.
ATP was prepared as a 100 mM stock in H2O and lyso-
phosphatidylcholine (LPC) was a 100 mM stock in 100%
methanol; both were stored at -20°C.
Data analysis
Data are expressed as mean ± s.e.m. and paired data sets
compared using two-tailed t-tests. For FlexStation
recordings, the numbers of experiments are indicated as
N/n, where N is the number of wells used in the 96-well
plate and n is the number of independent experiments
(i.e. different 96-well plates and batches of cells). All data
from primary cultures of FLSs derived from at least 3
independent patient samples. Statistical significance is
indicated by probability (P-value) of *P < 0.05 unless
specified; NS indicates no significant differences. Data
were handled, analysed and prepared for presentation
using Origin software (Origin Lab Corporation,
Northampton, CA, USA).
Results
Endogenous expression of TRPM3
Messenger RNA encoding TRPM3 was detected in FLSs
from patients with RA (Fig 1a). The TRPM3 protein was
expressed endogenously because anti-TRPM3 antibody
[11] labeled cells at the edge of the synovial lining in syn-
ovial biopsies (Fig 1b); the cells were CD55 positive (data
not shown), supporting identification as FLSs [3]. TRPM3
could also be detected in the sub-lining cell layer and in
blood vessels of the joint (Fig 1c).
Ca2+-entry evoked by sphingosine in HIG-82 cells
Because of limited supply of synovial biopsies we first
sought to investigate the functional relevance of TRPM3
expression through experiments on a FLS cell-line (HIG-
82 cells), a proposed model system of proliferating FLSs
in joints. As with synovial biopsies, there was labeling of
the cells by anti-TRPM3 (data not shown) and anti-CD55
antibodies [3].
TRPM3 channels are suggested to be Ca2+ permeable
and so we studied channel activity using an intracellular
Ca2+ indicator. Cells were exposed to sphingosine because
it has been suggested to stimulate human TRPM3 over-
expressed in HEK 293 cells [8]. In HIG-82 cells, sphin-
gosine elicited a rise in the intracellular Ca2+ concentra-
tion in two phases - an initial transient phase followed by
a sustained phase (Fig 2a). Dimethylsphingosine also
stimulated over-expressed human TRPM3 [8] and elic-
ited transient followed by sustained Ca2+ responses in
HIG-82 cells (Fig 2b).
The transient and sustained phases of the sphingosine
and dimethylsphingosine responses depended on the
presence of extracellular Ca2+ (Fig 2a, b), which suggested
that both phases were due to Ca2+-influx. It was conceiv-
able however that removal of extracellular Ca2+ caused
depletion of intracellular Ca2+ stores, leading to the false
impression of Ca2+-influx. To investigate this possibility
we applied extracellular ATP to activate G protein-cou-
pled purinoceptors. ATP elicited a predominantly tran-
sient rise in Ca2+  that was unaffected by removal of
extracellular Ca2+ (Fig 2c), showing that ATP acted by
evoking Ca2+-release and that Ca2+-stores had not been
inadvertently depleted. The data support the conclusion
that sphingosine evoked Ca2+ influx.
Role of TRPM3 in the sustained sphingosine response of 
HIG-82 cells
It was previously described that the anti-TRPM3 anti-
body TM3E3 has an inhibitory effect on human TRPM3
Figure 1 Expression of TRPM3 in FLSs of synovium in rheumatoid 
arthritis. (a) PCR products from analysis of mRNA isolated from prima-
ry cultured FLSs from patients with (+) and without (-) prior reaction 
with reverse transcriptase (RT). On the left is the DNA marker ladder 
(M). The expected TRPM3 mRNA product size is indicated with an ar-
row. (b) Serial sections of RA synovial biopsy labeled with the primary 
(1°) anti-TRPM3 antiserum present (left image) or absent (right image). 
Positive labeling is green. The scale bar is 50 μm. (c) A section of RA syn-
ovial biopsy labeled with anti-TRPM3 antiserum (brown) and counter 
stained with haematoxylin to label cell nuclei (purple). The lining of the 
synovium (i) and a blood vessel (ii) are indicated by arrows.
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over-expressed in HEK 293 cells [11]. We, therefore,
investigated the effect of TM3E3 on the sphingosine
response in HIG-82 cells. The sustained response to
sphingosine was clearly suppressed (Fig 3a, b). The tran-
sient response to sphingosine was either unaffected (Fig
3a) or slightly potentiated, with the mean data just reach-
ing statistical significance (Fig 3b). Evidence for specific-
ity of TM3E3 came from its lack of effect on the Ca2+
response evoked by the Ca2+-ATPase inhibitor thapsi-
gargin (Fig 3c, and see below). The data suggest that a
substantial component of the sustained response to
sphingosine was due to stimulation of TRPM3-contain-
ing Ca2+-influx channels.
Potential role of TRPV channels in the transient 
sphingosine response of HIG-82 cells
To gain insight into the TRPM3-independent transient
response we investigated its sensitivity to ruthenium red,
which is a non-specific inhibitor of TRP channels [1].
Ruthenium red was inhibitory (Fig 3d), consistent with
the transient response being substantially due to Ca2+-
influx and suggesting dependence on TRP channels [1].
Ruthenium red is best known as an inhibitor of the TRPV
subfamily of TRP channels. Therefore, we applied TRPV
channel stimulators in an effort to mimic the transient
effect of sphingosine.
4α-Phorbol 12,13-didecanoate (4-α-PDD) is an agonist
at TRPV4 channels and appears to be specific for this
channel type [21]. The compound elicited a Ca2+
response (Fig 3e), which suggested that functional
TRPV4 channels were expressed in the HIG-82 cells.
Removal of extracellular Ca2+  reduced the sustained
response to 4-α-PDD, although a transient response
remained (Fig 3e). The data suggest that TRPV4 channels
are functional at the plasma membrane. Consistent with
the notion that sphingosine caused transient Ca2+ entry
in HIG-82 cells because it stimulated TRPV4, sphin-
gosine evoked a similar transient rise of the intracellular
Ca2+ concentration in a cell-line stably expressing the
clone of human TRPV4 (Fig 3f).
Effect of sphingosine on primary FLSs
Sphingosine responses were also investigated in primary
cultures of FLSs from patients with RA to determine the
relevance of the HIG-82 cell data. As with HIG-82 cells,
sphingosine elicited sustained Ca2+  responses that
depended on extracellular Ca2+ (Fig 4a). In contrast to
HIG-82 cells, there was no transient response to sphin-
gosine (Fig 4a). Consistent with dominant contribution of
sustained Ca2+ entry and TRPM3 channels, TM3E3 anti-
body inhibited the response (Fig 4b). TM3E3 did not act
non-specifically because it had no effect on Ca2+
responses to ATP or lysophosphatidylcholine (LPC) (Fig
4c, d).
Effect of pregnenolone sulphate on primary FLSs
A recently-reported stimulator of TRPM3 channels is
pregnenolone sulphate [10]. Pregnenolone sulphate elic-
ited a robust rise in Ca2+ in FLSs from patients with RA
(Fig 5a). The response was abolished in the absence of
extracellular Ca2+ (Fig 5a) and the response to sphin-
gosine was not additive on top of the pregnenolone sul-
phate response (Fig 5b), suggesting that pregnenolone
sulphate and sphingosine stimulate the same Ca2+ influx
pathway. In support of this hypothesis, TM3E3 antibody
strongly inhibited the pregnenolone sulphate response
Figure 2 Sphingosine-evoked Ca2+ signals in HIG-82 cells. Data were generated by intracellular Ca2+ measurement. Responses elicited by (a) 
sphingosine (SPH, 20 μM), (b) dimethylsphingosine (DMS, 20 μM) or (c) adenosine triphosphate (ATP, 100 μM) were tested in either 1.5 mM Ca2+-con-
taining (+Ca2+) or Ca2+-free extracellular solution. Responses are each representative of 3 (n) independent experiments.
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(Fig 5c). Concentration-response curves were con-
structed to determine if the effect of pregnenolone sul-
phate on Ca2+-influx might be relevant to physiological
concentrations of the steroid. Concentrations of >1 μM
pregnenolone sulphate were effective at elevating the
intracellular Ca2+ concentration (Fig 5d), which are above
the known physiological concentrations of this steroid
[22,23].
Functional roles of TRPM3 and pregnenolone sulphate 
responses in primary FLSs
Hyaluronan is secreted by FLSs and its secretion is exces-
sive and pro-inflammatory in RA [17]. We hypothesized
that Ca2+  might modulate the secretion. Hyaluronan
secretion was, therefore, measured and first investigated
using the established positive controls tumour necrosis
factor and dexamethasone that stimulate and inhibit
hyaluronan secretion respectively; both compounds
acted as expected (Fig 6a). Like dexamethasone, preg-
nenolone sulphate inhibited hyaluronan secretion (Fig
6a). TM3E3 alone had no effect (Fig 6b) but prevented the
action of pregnenolone sulphate (Fig 6c). TM3E3 was
ineffective when it had been preadsorbed to its antigenic
peptide (Fig 6c), showing that its effect depended on the
TRPM3 peptide recognition site of the antibody.
Although dexamethasone also inhibited hyaluronan
secretion (Fig 6a), its effect was unchanged by TM3E3
(Fig 6d). The data suggest that stimulation of TRPM3
inhibited hyaluronan production or secretion.
Discussion
The data add to an emerging picture of multiple types of
TRP channel in fibroblast-like synoviocytes (FLSs) [3,4],
specifically suggesting that TRPM3 channels enable sus-
Figure 3 Inhibition of sustained sphingosine responses by anti-TRPM3 antibody in HIG-82 cells. Data were generated by intracellular Ca2+ 
measurement. (a) Cells were pre-treated with 1:4000 dilution of pre-immune serum (pre-imm.) or anti-TRPM3 antiserum before observing responses 
to 20 μM sphingosine (SPH). (b) Summary normalised data from 8 independent experiments showing inhibitory effect of TM3E3 on the sustained 
response to SPH. (c) Lack of effect of TM3E3 on Ca2+ entry in cells store-depleted by 1 μM thapsigargin (TG) for 30 min in Ca2+-free extracellular solution 
followed by re-addition of 1.5 mM Ca (+Ca2+); representative of N/n = 24/3. (d-f) Investigation of the transient response to SPH. (d) Effect of 10 μM 
ruthenium red (+RR.) on the SPH response in HIG-82 cells; representative of N/n = 12/3. (e) Responses to 10 μM 4α-phorbol 12,13-didecanoate (4α-
PDD) in HIG-82 cells in the presence (+Ca2+) and absence of extracellular Ca2+; representative of N/n = 16/2. (f) Representative of 3 independent ex-
periments, responses to sphingosine (SPH, 20 μM) in CHO cells stably expressing TRPV4.
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tained Ca2+ responses to sphingosine and pregnenolone
sulphate. Of potential functional relevance was the obser-
vation that pregnenolone sulphate acted via TRPM3 to
negatively modulate hyaluronan secretion, independently
of the pathway activated by glucocorticoids. The data,
therefore, suggest a molecular basis for therapeutic bene-
fit of pregnenolone in rheumatoid arthritis, as initially
suggested in publications of the 1950s and commonly
suggested in the contemporary field of dietary supple-
mentation.
We cannot exclude that endogenous concentrations of
pregnenolone sulphate (or a related steroid) become suf-
f i c i e n t l y  h i g h  i n  R A  t o  s t i m u l a t e  T R P M 3  i n  F L S s  b u t
there is currently no evidence to support such a hypothe-
sis. Small effects of the related steroids pregnenolone,
dehydroepiandrosterone (DHEA) and DHEA sulphate
(DHEA-S) were observed, but again the concentrations
are unlikely to be physiologically relevant. Physiological
DHEA-S concentrations are high (3-4 μM in patients with
RA [24]) but we observed only minor effects of 100 μM
DHEA-S on Ca2+ in primary cultures of FLSs and no
effects of lower concentrations (C Ciurtin et al, unpub-
lished data).
There is greater reason to suggest that the effect of
pregnenolone sulphate on Ca2+ entry in FLSs is pharma-
cologically interesting because pregnenolone (much of
which is sulphated in vivo) is self-administered as a
dietary supplement and informally considered to have
general health-giving benefits, including in RA. There are
on-going clinical trials of pregnenolone or related ste-
roids to rigorously test the benefits and adverse effects,
but not yet in RA. Reasons why pregnenolone might be
considered are as follows: (i) a range of small-scale studies
published in the early 1950s suggest that pregnenolone
may be of benefit in RA (Additional file 1); (ii) our data
suggest a mechanistic basis for a beneficial action of preg-
nenolone in RA (i.e. inhibition of hyaluronan secretion
via TRPM3 stimulation); (iii) Pregnenolone has been
Figure 4 Ca2+-entry evoked by sphingosine (SPH) in primary cultures of FLSs from patients with RA. (a) Intracellular Ca2+ measurement show-
ing the effect of external application of 20 μM SPH in the presence and absence of extracellular Ca2+. (b-d) Intracellular Ca2+ measurements showing 
responses to externally applied substances: (b) 20 μM SPH, (c) 100 μM adenosine triphosphate (ATP), and (d) 30 μM lysophosphatidylcholine (LPC). In 
paired experiments on the same 96-well plate, responses were compared after pre-treatment with anti-TRPM3 antibody (TM3E3) or TM3E3 pread-
sorbed to its antigenic peptide ("+pep."; control group). (a-d) All data points are N = 8 and representative of 3 (n) independent experiments.
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taken orally at high concentrations and remains readily
available, yet major adverse effects are not apparent; (iv)
Readily tolerated concentrations of pregnenolone are
expected to generate sufficient plasma concentrations of
pregnenolone sulphate to stimulate TRPM3 and inhibit
hyaluronan secretion; (v) the mechanism of action of
pregnenolone is distinct from that of dexamethasone and
it is expected to lack the unwanted effects of glucocorti-
coids. Although pregnenolone is the precursor for all ste-
roid hormones, administration of pregnenolone does not
appear to elevate concentrations of sex steroids, presum-
ably because of sulphation and rate-limiting steps in ste-
roid hormone synthesis. A reason not to consider
pregnenolone as potentially clinically relevant in RA is
that the field has moved forward enormously since the
studies of the 1950s. Can an endogenous steroid be seri-
ously considered at time of major breakthroughs in bio-
logical (antibody) drug treatment? We suggest that it may
have a valuable role to play but that rigorous clinical trials
would be needed first. The potentially low cost of preg-
nenolone could be attractive to health providers and
pregnenolone could confer a useful addition to therapeu-
tic options during flare or during periods of remission
after biological therapy.
It was reported that sphingosine and dimethylsphin-
gosine stimulate over-expressed human TRPM3 [8] and
we confirmed this observation when transiently express-
ing the same clone [11]. Another research group sug-
gested that sphingosine is ineffective as a stimulator of
TRPM3 and has non-specific effects [10]. We do not
know the explanation for the difference but our data on
endogenous TRPM3 of FLSs supports the view that
Figure 5 Ca2+-entry evoked by pregnenolone sulphate (PregS) in primary cultures of FLSs from patients with RA. (a) Intracellular Ca2+ mea-
surement showing the effect of external application of 100 μM PregS in the presence and absence of extracellular Ca2+. (b) As for (a) but the effect of 
PregS (100 μM) and then addition of 20 μM SPH. (c) As for (a) but paired experiments on the same 96-well plate where responses were compared after 
pre-treatment with anti-TRPM3 antibody (TM3E3) or TM3E3 preadsorbed to its antigenic peptide ("+pep."; control group). (a-c) All data points are N 
= 8 and representative of 3 (n) independent experiments. (d) Concentration-dependence of Ca2+-entry evoked by PregS. Mean data are shown for 
measurement of the peak and sustained responses to PregS (e.g. see (c)); 4 (n) independent experiments. The fitted curves are Hill equations with mid-
points at 35.7 μM (peak) and 39.5 μM (sustained). The shaded area on the left (i) indicates the highest concentrations reported for endogenous PregS 
[22,23], while the shaded area on the right (ii) indicates the higher concentrations of plasma PregS predicted on oral administration of 100 mg daily 
to adult humans.
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sphingosine stimulates TRPM3; nevertheless, we have no
strong argument for it as a physiological regulator of
TRPM3.
We previously evaluated anti-TRPM3 antibody,
TM3E3, against the function of human TRPM3 over-
expressed in HEK 293 cells [11]. The antibody had a
blocking effect in a variety of assays but it was striking
that the effect was only partial (<50% inhibition). It was
therefore surprising to find such a strong effect in FLS
studies. The greater effect may have arisen because the
FLS studies involved endogenous TRPM3, with normal
expression and degradation mechanisms. In HEK 293 cell
over-expression studies, expression is driven at a high
rate, conferring rapid replacement of channels at the cell
surface and possibly saturation of degradation mecha-
nisms. We suspect that the antibody inhibits channels, at
least in part, via a mechanism that requires channel inter-
nalization. Therefore, over-expression studies may under-
estimate the degree of block because new channels
replace antibody-bound channels and internalization of
bound channels is slow.
Conclusions
The data suggest expression and function of TRPM3
channels in cells that line the synovium of joints of
patients suffering from rheumatoid arthritis. TRPM3
could also be detected in cells of the sub-lining layer and
in small blood vessels of the joints, consistent with a
recent report of vascular TRPM3 expression [25]. The
channels may be stimulated by sphingosine or preg-
nenolone sulphate but the physiological relevance of
these stimulators is uncertain. Instead we discuss argu-
ments for further investigation of pregnenolone as a
treatment for RA, acting in part through negative cou-
Figure 6 Negative coupling to hyaluronan secretion in primary cultures of FLSs from patients with RA. Data are from measurements of hy-
aluronan derived from cells of 6 (a-c) or 3 (d) patient samples. (a) Mean effects of 100 μM pregnenolone sulphate (PregS), 10 ng/ml tumor necrosis 
factor (TNF) and 1 μg/ml dexamethasone; 'control' was the solvent. (b) Mean data showing no effect of anti-TRPM3 antibody (TM3E3) on basal hy-
aluronan secretion; one control was without TM3E3 (no Ab) and another was from cells pretreated with TM3E3 preadsorbed to its antigenic peptide 
(TM3E3 + pep.). (c) As for (b) but showing the effect 100 μM PregS under the different antibody (Ab) conditions; the control was cells without PregS. 
(d) Failure of TM3E3 to protect against the inhibitory effect of 1 μg/ml dexamethasone.
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pling to hyaluronan and potentially lacking unwanted
effects of glucocorticoids. Overall, the data add to an
emerging picture of TRP channel function in the syn-
ovium and suggest previously unrecognized regulation of
hyaluronan secretion by ion channel activity at the
plasma membrane.
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